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The global prevalence of diabetes is estimated to be 336 million people, with diabetic complications contributing to signiﬁcant
worldwide morbidity and mortality. Diabetic retinopathy results from cumulative microvascular damage to the retina and
inﬂammation is recognized as a critical driver of this disease process. This paper outlines the pathophysiology leading to
proliferative diabetic retinopathy and highlights many of the inﬂammatory, angiogenic, and cytokine mediators implicated in
the development and progression of this disease. We focus a detailed discussion on the current targeted therapeutic interventions
used to treat diabetic retinopathy.
1.Introduction
The global prevalence of diabetes is estimated to be 336
millionpeople,andthisnumberisprojectedtonearlydouble
by 2030 [1, 2]. In addition to the primary disease itself,
diabetic complications are expected to have profound impli-
cations for the future of patient management. Diabetes is
a disease of hyperglycemia, and diabetic retinopathy (DR)
results from cumulative microvascular damage to the retina.
According to the World Health Organization, DR accounts
for approximately 5% of global blindness [3]. Inﬂammation
is a critical driver of the pathophysiology of DR [4]. This
paper highlights many of the inﬂammatory, angiogenic, and
cytokine mediators implicated in the development and pro-
gression of DR and features speciﬁc and targeted therapeutic
modalities to combat retinopathy.
2.PathwaystoDamage
Two major studies, the Diabetes Control and Complications
Trial (DCCT) of 1993 and the United Kingdom Prospective
Diabetes Study (UKPDS) of 1998, have demonstrated that
hyperglycemia is the causative etiology for DR [5, 6].
Hyperglycemia causes microvascular changes, that in turn
results in retinopathy. At least four distinct biochemical
pathways have been suggested for the mechanism leading
to retinopathy. These include increased polyol pathway ﬂux,
increased advanced glycation end product (AGE) formation,
activation of protein kinase C (PKC) isoforms, and increased
hexosamine pathway ﬂux. Taken together, these pathways
result in oxidative stresses and inﬂammation that attenuate
vascular wall integrity and result in increased vascular per-
meability, occlusion, and ischemia [7, 8]. These types of
microvascular insults manifest in increased vascular leakage,
as in nonproliferative retinopathy (NPDR), and retinal neo-
vascularization secondary to ischemia, as in proliferative
retinopathy (PDR) [9, 10].
There is increasing evidence that inﬂammation has a
central role in the pathophysiology of diabetic retinopathy
[4, 11]. Indeed, as early as 1964, it was noted that patients
suﬀering from rheumatoid arthritis demonstrated less severe
PDR if taking high dose aspirin [10]. In his review of the
literature, Adamis similarly concludes that diabetic retinopa-
thy is an inﬂammatory disease [4, 12]. He describes the
orderly chronological progression of the disease process,
brieﬂy described here. Within a single week of experimental
diabetes, prior to any clinical sign of diabetic retinopathy,2 Mediators of Inﬂammation
inﬁltrating leukocytes adhere to retinal vasculature. Over
time, a subset of these leukocytes accumulate and transmi-
gratetotheretina.Usingtheirβ2 integrins,VLA-4,andCD18
surface molecules, leukocytes latch onto the local vasculature
via leucocytes adhesion molecules present on the endothe-
lium, such as intercellular adhesion molecule-1 (ICAM-1),
vascular cell adhesion molecule-1 (VCAM-1), PECAM-1,
and P-selectin [11–14]. In fact, early DR is marked by a
disorderly upregulation of these adhesion molecules, pre-
cisely when leukocyte numbers begin to increase [15]. Once
leukocytes attach to the vascular epithelium, inﬂammatory
cytokines, growth cytokines, and vascular permeability fac-
tors are released, altering endothelial junctional proteins
and allowing for leukocytic diapedesis into the retina, with
concurrent compromise to the blood-retinal barrier (BRB)
[4]( Figure 1).
3. Mediatorsof Damage
The upregulation of numerous factors, both angiogenic and
inﬂammatory, has been implicated in the pathogenesis of
microvascular retinopathy. Again, the expression of vascular
adhesion molecules such as ICAM-1, VCAM-1, and various
selectin molecules is required for leukocytic recruitment to
inﬂammatory sites [16]. Vascular endothelial growth factor
(VEGF) is an angiogenic compound that under hypoxic or
ischemicconditions(asinproliferativeDR)encouragesaber-
rant vasculature. Inﬂammatory factors including the inter-
leukins, tumor necrosis factor (TNF), insulin-like growth
factor (IGF), angiopoietins (Ang-2), among many others
have all been studied and implicated in the pathophys-
iological pathways leading to clinical PDR [4, 8]. These angi-
ogenic,adhesion, andinﬂammatorymoleculeshavebeenthe
focus of targeted therapies to treat DR.
4.VEGF
VEGF is a member of a large family of angiogenic growth
factors, a group consisting of six known members: VEGF-A
(referredtoassimplyVEGF),placentalgrowthfactor,VEGF-
B, VEGF-C, VEGF-D, and VEGF-E. VEGF-A is the ﬁrst and
major form involved in angiogenesis. It increases the rate of
mitosis and migration of endothelial cells and is involved in
integrin αvβ3 regulation as well as creation of blood vessel
lumen and fenestrations. In addition, it is chemotactic for
macrophages and granulocytes and leads indirectly, via NO
release, to vasodilation. VEGF-B is involved in embryonic
angiogenesis, speciﬁcally in myocardial tissue. VEGF-C is a
major prolymphangiogenesis factor, and VEGF-D is needed
for the development of bronchiolar lymphatic vasculature.
VEGF-E is found in viruses. PlGF is important in vasculo-
genesis, but plays a role in ischemia induced angiogenesis as
well as inﬂammation and wound healing.
Though initially recognized as a vascular permeability
factor, VEGF was subsequently recognized for its angiogenic
properties and as a speciﬁc mitogen for vascular endothelial
cells. In the context of PDR, these two ﬁndings suggest that
VEGF could account for both the proliferation and vasoper-
meability witnessed in the disease progression. In addition
to its involvement in DR, signiﬁcant evidence implicates
VEGF in the pathogenesis of diabetic retinopathy, retinopa-
thy of prematurity, age-related macular degeneration, and
corneal neovascularization. A simpliﬁed mechanism follows.
Pathologic angiogenesis relies on the aberrant activation of
proteases and various degratory enzymes emanating from
the endothelium that allow for endothelial cells to leave the
parental vasculature and proliferate in the matrix. Increased
levels of ocular VEGF in PDR only reinforces the role
of neovascularization in the course of this disease. Recent
successes with anti-VEGF therapy for age-related macular
degeneration in the MARINA and ANCHOR studies have
prompted signiﬁcant eﬀorts to translate the application of
anti-VEGF drugs to DR [17, 18].
Some forms of VEGF are more deleterious than others.
Two major VEGF isoform splice variants, VEGF120(121) and
VEGF164(165), were compared in the transparent and avas-
cular adult mouse cornea. VEGF164(165) was found to be
signiﬁcantly more potent at inducing corneal inﬂammation,
stimulating ICAM-1 expression on endothelial cells, and
inducing monocytic chemotaxis than VEGF120(121). Of the
two major VEGF isoforms, VEGF164(165) was demonstrated
to be more eﬀective in inducing inﬂammation, neovascular-
ization, and angiogenesis in the cornea [19].
As early as 1994, Aiello and Cavallerano demonstrated
that individuals with PDR have elevated levels of vitreal
VEGF, and that laser photocoagulation therapy signiﬁcantly
reduces these levels [9]. Shortly thereafter, Robinson et al.
showed that blocking VEGF obviated the development of
proliferative retinopathy in murine models [20]. Moreover,
demonstrating the opposite eﬀect, Tolentino et al. adminis-
tered intravitreal VEGF injections and reported the ability to
induceiris neovascularization and retinopathy in nonhuman
primates [21].
These promising bench studies prompted eﬀorts for
a clinical intervention that would target VEGF for the
treatment of PDR. Knowing that the pathophysiology of DR
can be explained in the context of a leukocytic invasion
with a concurrent inﬂammatory disorder, Lu et al. found
that VEGF increases retinal vascular expression of ICAM-
1 in vivo, and subsequent studies demonstrated that VEGF
provides important chemotaxis for monocytes [22]. Joussen
et al. similarly showed that retinal VEGF induces ICAM-
1 expression and initiates early diabetic retinal leukocyte
adhesion in vivo, and that blocking VEGF decreases retinal
leukocyte counts in experimental diabetes [23].
VEGF has been the target of numerous drugs and
clinical trials for the treatment of diabetic macular edema
(DME) and PDR. VEGF inhibitors include the antibody
bevacizumab (Avastin, Genentech Inc., San Francisco, USA),
the monoclonal antibody fragment Ranibizumab (Lucentis,
GenentechInc.,SanFrancisco,USA),anaptamerpegaptanib
(Macugen, OSI Pharmaceuticals), the soluble VEGF receptor
analogs, VEGF-Trap (Regeneron Pharmaceuticals, Tarry-
town, NY, USA), small interfering RNAs (siRNAs) bevasir-
anib (Opko Health Inc., Miami, FL, USA), and rapamycin
(Sirolimus, MacuSight Inc., Union City, CA, USA) [8]. TheMediators of Inﬂammation 3
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Figure 1: Normal eye (a) with intact vasculature (b). Accumulation of microvascular diabetic changes in the eye (c) manifest in adverse
cellular changes with ultimate compromise to the blood-retinal-barrier (d).
application of anti-VEGF medications for PDR remains oﬀ-
label, as the safety and eﬃcacy of these drugs have not been
deﬁnitively established [24].
Though anti-VEGF drugs have been studied extensively
f o rD M E ;n ol a r g ep r o s p e c t i v era n d o m i z e ds t u d i e sh a v eb e e n
published to date for the application of these agents for
PDR. A retrospective study evaluating eyes with PDR treated
with intravitreal bevacizumab demonstrated that complete
resolution of neovascularization of the disc (NVD) was
noted in 73% of the treated eyes on ﬂuorescein angiography
(FA) [25]. In 2008, Mirshahi et al. showed that 87.5%
of eyes injected with bevacizumab demonstrated complete
neovascularization regression at within six weeks, though
this eﬀect was temporary, as by four months the beneﬁts
of bevacizumab were strongly attenuated [26]. In 2011,
Schmidinger et al. found that a 3-monthly bevacizumab
retreatment regiment may be a valid method to control
persistent neovascularization in PDR patients after complete
panretinal photocoagulation (PRP) [27]. Other studies con-
ﬁrm that intravitreal bevacizumab decreases leakage from
diabetic neovascular lesions and may prove to be of utility
as an adjunct when it comes to vitreous hemorrhage, post-
PRP macular edema, neovascularization of the iris, pars
plana vitrectomy for tractional retinal detachment, non-
clearing vitreous hemorrhage, and as a prevention against
exacerbation of DME after cataract surgery [24, 28]. Though
anti-VEGF drugs seem promising, the lack of randomized,
prospective trials, standard dosing schedules, and admin-
istration protocols limits their current role to adjunctive
therapies for PDR [24].
Though promising, VEGF therapy is not without risks.
While numerous studies have posited the neuroprotective
role of VEGF, there is a possible neurodegenerative risk with
prolonged pan-VEGF blockade. Indeed, it has been shown
thatVEGFdemonstratesneuroprotection,neurogenesis,and
angiogenesis in the ischemic brain: VEGF promotes the
formation of new cerebral blood vessels in response to cere-
bral ischemia, reduces cerebral infarct volume and edema,
reducesneurologicdeﬁcitsandimprovesneurologicrecovery
outcomes, and inﬂuences cerebral neurogenesis in the adult
brain [29–32]. Moreover, data suggest that VEGF is endowed
with anticonvulsant properties and that VEGF protects
against hippocampus neuronal loss after status epilepticus
[33, 34]. Though further investigation is indicated, it has
been suggested that chronic pan-VEGF blockade can have
deleterious eﬀects leading to retinal neurodegeneration and
choriocapillary circulatorydisturbances. Indeed, VEGF inhi-
bition or blockade may exacerbate ischemic injury and neu-
raldamage[35].Nishijimaetal.demonstratedtheimportant
role of VEGF for retinal neural survival in ischemic-
reperfusion injury [36]. The same authors also noted that
chronic inhibition of VEGF in normal adult animals led to a4 Mediators of Inﬂammation
signiﬁcant loss of retinal ganglion cells. These considerations
must be taken into account when treating patients with
VEGF for age-related macular degeneration or PDR.
5.ICAM
Leukocyte adhesion to the vasculature is an important initial
step in the progression of endothelial cell injury and diabetic
retinopathy. This initial insult is mediated through ICAM-
1 and the leukocyte integrin CD18. ICAM-1 is directly
involvedinimmuneactivationandinﬂammationthroughits
interaction with diﬀerent cytokines, including IL-1, TNF-α,
and IFN-γ [37, 38]. In 1995, McLeod et al. noted enhanced
expression of ICAM-1 and P-selectin in the diabetic human
retina and choroid. The authors demonstrated an increase
in leucocyte density in human eyes with DR, as well as
an increase in retinal vascular ICAM-1 immunoreactivity
[39]. Similarly, Esser et al. demonstrated higher levels of
soluble ICAM-1 in PDR and in traumatic PVR, showing
concentrations that were signiﬁcantly elevated above total
vitreal protein levels [40].
Adamiec-Mroczek and Oﬁcjalska-Mły´ nczak explored
variations of vitreous ICAM-1, VCAM-1, IL-6, and TNF-
α concentrations in the development of PDR [41]. The
authors found that both vitreous and serum soluble adhe-
sion molecules (ICAM-1, VCAM-1) and proinﬂammatory
cytokine (IL-6, TNF-α) levels were signiﬁcantly higher in
patients with PDR than in controls. Further, they found that
these increases in adhesion molecule levels correlated with
high vitreous concentrations of IL-6 and TNF-α in patients
with PDR, providing more evidence of the inﬂammatory
nature of PDR. A positive correlation between vitreous solu-
ble VCAM-1 and serum HbA1c concentrations bolstered the
connection between hyperglycemia and adhesion molecule
proliferation.
While it had been previously established that increased
serum levels of soluble ICAM-1, VCAM-1, and E-selectin
may be found in patients with chronic inﬂammatory or ocu-
lar diseases, Limb et al. found that vitreous levels of ICAM-1,
VCAM-1, and E-selectin were similarly signiﬁcantly higher
in eyes with PDR than in control cadaveric vitreous. Again,
the connection between inﬂammation, ICAM expression,
a n dD Ri sr e a ﬃrmed [42].
Barile et al. similarly measured vitreous levels of soluble
ICAM-1 and VCAM-1 in the eyes of patients with retinal
detachment (RD) due to proliferative diabetic retinopathy
(PDR) or proliferative vitreoretinopathy (PVR). The authors
found that soluble ICAM-1 and VCAM-1 are signiﬁcantly
increased in the vitreous cavity of patients with RD due to
PDR or PVR when compared to control vitreous [43].
Research on ICAM-1 has highlighted its potential as
a target of therapeutic intervention for the treatment of
PDR. Joussen et al. treated animals with 50mg/kg of aspirin,
meloxicam (a cyclo-oxygenase-2 inhibitor), or etanercept (a
soluble TNF-α receptor) [44]. The authors found that all
three agents were found to reduce retinal ICAM-1 expres-
sion. Aspirin was further found to reduce the expression of
CD11a, CD11b, and CD18. Each of the three agents reduced
leukocyte adhesion and hindered BRB breakdown. Aspirin
and meloxicam both lowered retinal TNF-α levels. None of
the above three agents had any eﬀect on VEGF levels.
Recently, Hirano et al. described a novel therapeutic
option for the treatment of DR by targeting ICAM-1.
Hypothesizing that control over ICAM-1 expression should
prevent the earliest stages of retinopathy, the authors applied
small-interfering RNA (siRNAs) through a hydrodynamics-
based transfection technique (HT) and intravitreal injection
(IV) to a murine retina in vivo.E ﬃcient modulators of gene
expression, siRNAs bind to speciﬁc mammalian RNA targets
and suppress target gene expression posttranscriptionally.
The authors concluded that siRNA causes speciﬁc downreg-
ulation of ICAM-1 expression, suggesting a mechanism to
inhibiting leukocyte inﬁltration and adhesion in early stage
PDR [45].
Researchers have identiﬁed other promising targets
related to adhesion molecules. Fasudil, a selective ROCK
inhibitor, is one prime example. The Rho/ROCK pathway
promotes leukocyte adhesion to the microvasculature by
increasing ICAM-1 expression and aﬀecting the function of
various adhesion molecules. Intravitreal fasudil was found to
reduce ICAM-1 expression, leukocyte adhesion, and endo-
thelial apoptosis in the retinas of diabetic rats [46]. Another
example is periostin, a matricellular protein with roles in
cell adhesion and migration. Periostin has been associated
with the formation of preretinal ﬁbrovascular membranes,
structures that form in advanced PDR that causes blind-
ness through intravitreal hemorrhage and tractional retinal
detachment.Onestudyhassuggestedthattargetingperiostin
may be a potential therapy for inhibiting ﬁbrovascular mem-
branes associated with PDR [47].
6. Inﬂammatory Mediators
Numerous studies have demonstrated signiﬁcant increases
in soluble ICAM-1 and VCAM-1 levels in patients with
PDR, with corresponding elevations in vitreous IL-6 and
TNF-α concentrations. These observations corroborate the
inﬂammatory and immune natures of the pathophysiology
of PDR.
Two of the aforementioned studies noted an attenuation
of TNF-α levels when treated with anti-inﬂammatory med-
ications [41, 44]. This is signiﬁcant because TNF-α plays an
important role in neovascularization and vascular reactivity,
in addition to its proinﬂammatory properties. TNF-α is
directly involved in inﬂammation through an induction
of cytokines, involvement in monocyte chemotaxis, and
stimulation of adhesion molecules on retinal endothelium
[48].
Focusing on TNF-α, Limb et al. measured soluble TNF-
receptors (sTNF-Rs, types I and II) in patients with various
retinal pathologies and found that vitreous levels of sTNF-
Rs were signiﬁcantly increased in eyes with PDR when
compared with control eyes. Further, the authors found
that the increased vitreous levels of sTNF-Rs correlate with
the degree of retinopathy severity and posit that eﬀective
control of TNF-α activity by sTNF-Rs within the retinal
microenvironment may determine the outcome and severity
of retinal proliferative conditions [49].Mediators of Inﬂammation 5
Other studies demonstrate that inﬂammatory mediators
cause gradual damage as retinopathy progresses. Gustavsson
et al. measured levels of IL-1b, IL-6, and TNF-α through
ELISA analysis and found that vitreous IL-6 and serum
TNF-α levels were higher in diabetic patients than in non-
diabetics. The authors concluded that intraocular inﬂamma-
tion is involved in PDR but does not seem to be promi-
nent in nondiabetic retinopathy, nonproliferative diabetic
retinopathy, or even in those progressing to early retinopathy
stages. Those with PDR, however, had signiﬁcantly more
inﬂammatory activity, as evidenced by the increased serum
levels of IL-6 and TNF-α [3].
Similarly, Yuuki et al. measured concentrations of IL-6,
IL-8, and TNF-α via ELISA in the vitreous and serum of
patients with PDR and vitreous noninﬂammatory retinop-
athies. Vitreous concentrations of IL-6 and IL-8 were signiﬁ-
cantlygreaterinpatientswithPDRthaninnoninﬂammatory
retinopathies, and serum TNF-α was signiﬁcantly greater
in PDR than in noninﬂammatory retinopathies (this latter
ﬁnding was limited to the serum but did not hold true in
the vitreous). The authors postulated that these signiﬁcant
increases in IL-6, IL-8, and TNF-α may be diagnostically
usefulinPDRmanagement[50].Otherstudieshavesimilarly
found vitreal increases in IL-6 and IL-8 in PDR.
Inﬂammatory cytokines enhance leukocyte adhesion to
endothelium, vascular permeability, and thrombus forma-
tion by inducing procoagulant and inhibiting anticoagulant,
activity. Adamiec-Mroczek et al. collected vitreous and
serum samples of patients with proven PDR in order to
establish the role of inﬂammatory-proliferative processes of
the endothelium in this disorder [51]. The authors found
that vitreal and serum concentrations of endothelin-1 (ET-
1), TNF-α, IL-6, vWF, and E-selectin were higher in patients
with PDR than in controls. Moreover, the mean vitreous ET-
1 level in the PDR patients was signiﬁcantly higher than in
the control group, and its serum concentration was higher in
patients with PDR by a factor of seven.
While IL-6 and IL-8 hold a prominent place in the
inﬂammatory process, other cytokines also play prominent
roles. Zhou et al. measured the vitreal concentrations of IL-
1B, IL-6, IL-8, IL-10, CCL2, endothelin 1 (EDN-1), VEGF,
and TNF-α in patients with PDR and in controls with
ELISA. The authors found that with the exception of IL-
10, the concentrations of all the aforementioned factors were
considerably higher in PDR patients than in controls [52].
They also found a signiﬁcant positive correlation between
vitreous TNF-α, EDN1, and serum HbA1c levels in PDR
patients. These results add support to the role of inﬂam-
matory cytokines and angiogenic factors in the genesis of
PDR.
Chemokines are yet another potential target for thera-
peutic intervention for PDR. Bian et al. demonstrated that
one particular chemokine, CCL2, is an important factor in
initiating leukocyte recruitment and activation, especially in
thecontextofhyperglycemia.LevelsofCCL2aresigniﬁcantly
elevated in the vitreous of patients with DR when compared
to controls. CCL2 (also referred to as MCP-1) is the most
common chemokine that is signiﬁcantly elevated in the
serum and vitreous [53]. Moreover, CCL-2 levels have been
found to correlate with the severity and clinical stage of
DR [54]. Various studies have identiﬁed other cytokines and
chemokines signiﬁcantly elevated in both the serum and
vitreous of those suﬀering from DR. As CCR2 inhibitors are
beingstudiedinclinicaltrialstotreatinﬂammatorydisorders
suchasatherosclerosis,multiplesclerosis,rheumatoidarthri-
tis, and systemic lupus erythematosus, similar chemokines
are currently being studied under animal models as potential
therapeutic targets for the treatment of PDR.
While it seems that inﬂammatory mediators dominate
the pathogenesis of PDR, other mediators and chemokines
are important in the pathophysiology of the disorder. Recog-
nizing that any growth factors present in the inert vitreous
(protected by the BRB) are likely a reﬂection of retinal
production. Pfeiﬀer et al. measured and found that insulin-
like growth factor I (IGF-I), IGF-II, IGF binding protein
2 (IGFBP-2), and IGFBP-3 were elevated 3–13 fold in
nondiabetic retinal ischemia and 1.5–3 fold in PDR [55].
Though clearly not speciﬁc to one disorder,these changes
suggest that BRB breakdown and subsequent serum leakage
into the vitreous is an important aspect of the pathogenesis
of PDR and is a promising target for intervention.
Moreover, the same authors investigated vitreal TGF-β2,
asitisaproposedantiangiogenicfactorintheeye[55].While
the authors noted that total TGF-β2l e v e l sw e r en o ta l t e r e d ,
the active fraction of TGF-β2 was decreased by 30% in PDR
patients. As plasmin is thought to control TGF-β2 activation,
theauthorsdemonstratedthatserumproteinα2-antiplasmin
was signiﬁcantly elevated in PDR patients to 150% of control
values. This ﬁnding suggests that the ﬂow of serum markers
into the vitreous due to microvascular alterations is another
potential target for therapeutic intervention.
Microvascular changes and damage to the BRB con-
tribute to the pathogenesis of PDR. Shiels et al. furthered the
hypothesis that there is a direct relationship between plasma
leakage from damaged retinal vasculature and the prolifer-
ation and phenotypic change of RPE cells with ﬁbroblasts.
These latter cells, once damaged, contribute to retinopathies
by secreting matrix molecules such as ﬁbronectin and
expressing deviant surface antigens. The authors posit that
controlofthisinﬂammation-inducedvascularleakagewould
prove an important future target against microvascular
damage.
Angiopoietins, inﬂammatory growth factors that bind to
tyrosine kinase receptors, are yet other potential targets for
the treatment of BRB compromise [8]. Patel et al. attributed
BRB compromise as the reason for the elevated levels of
angiopoietin-2 (Ang-2) in the vitreous of patients with
clinically signiﬁcant macular edema (CSME) [56]. In the
same vein, Rangasamy et al. found that intravitreal injection
of Ang-2 in non-diabetic rats resulted in a multifold increase
in retinal vascular permeability, and that Ang-2 leads to
a loss of VE-cadherin function as well [57]. Fiedler et al.
demonstrated that Ang-2 sensitizes endothelial cells to TNF-
α induced expression of ICAM-1, the critical player in the
pathogenesis of inﬂammation-induced retinopathy [58].
Proteinases are yet another class of factors involved in
the progression of PDR. Parks et al. demonstrated that
metalloproteinases (MMPs) are important modulators of6 Mediators of Inﬂammation
innate immunity and inﬂammation, both acute and chronic
[59]. Speciﬁc MMPs have been implicated in PDR. Giebel
et al. found that the retinas of diabetic animals demonstrated
elevatedlevelsofMMP-2,MMP-9,andMMP-14mRNA,and
that the production of MMP-9 was especially increased in
cells exposed to a hyperglycemic environment. Ultimately,
cells treated with puriﬁed MMP-2 or MMP-9 demonstrated
degradation of occludin, a tight junction protein [60]. Jin
et al. also found that vitreal levels of MMP-9 were higher
in diabetic patients with retinopathy than in controls [61].
Navaratna et al. found that the proteolytic degradation
of VE-cadherin, a cell-to-cell junction protein, alters the
blood-retinal barrier in diabetes and decreases vascular
permeability [62]. The ramiﬁcation of these studies suggests
that MMPs are an important potential target for the control
of PDR progression.
Many other factors related to inﬂammation play a role
in PDR. Augustin et al. found that lipid peroxide levels and
myeloperoxidase activity was elevated in patients with PDR,
suggesting the role of oxygen free radicals complementing
the inﬂammatory pathogenesis of diabetic retinopathy [63].
7.Other Targets
Another target to prevent retinal angiogenesis and neo-
vascularization in the context of PDR has been aimed at
protein kinase C (PKC). The PKC enzymes, especially the
beta isoforms, are found in high levels in the retina.
Activator molecules, often induced by tissue hypoxia, result
in increased VEGF expression. Thus, eﬀorts have been aimed
at inhibiting PKC beta enzymes, those speciﬁcally found in
the retina, with low systemic toxicity. Selective inhibition
of the PKC beta isoform prevents VEGF-mediated cell
growth inutero and has been shown to reduce ischemia-
related retinal neovascularization in vivo [64]. Indeed, Ishii
et al. demonstrated that oral administration of a PKC-beta
inhibitor reduces diabetes related vascular permeability and
changes in retinal blood ﬂow [65]. Various PKC inhibitor
compounds have already been developed, such as ruboxis-
taurin, and several are in phase III clinical trials [66–72].
While the initial results of the multicenter randomized trial
from the Protein Kinase C β Inhibitor Diabetic Retinopathy
Study (PKC-DRS) group noted no statistically signiﬁcant
eﬀect of ruboxistaurin at any of the three treatment doses
for the progression of DR by their primary outcome
measurements after a minimum followup of 3 years, they
did note the eﬀects of the PKC inhibitor on their sec-
ondary outcome, moderate visual loss (MLV), and sustained
moderate visual loss (SMVL) [67]. Indeed, the PKC-DRS2
group subsequently studied this latter eﬀect in more detail
and concluded that ruboxistaurin reduces the occurrence of
SMVL by 40% in patients with moderately severe to very
severe nonproliferative diabetic retinopathy, while increasing
the likelihood of visual improvement by a factor of two [66].
Fenoﬁbrates and statins have recently been suggested
to be a therapy for PDR, due to their secondary anti-
inﬂammatory and oxidative properties rather than their
primary eﬀects on lipid levels. Studies have demonstrated
that simvastatin treatment of diabetic rats resulted in the
retinal suppression of superoxide formation and decreased
expression of VEGF, angiopoietin 2, and erythropoietin [73].
Two recent major randomized clinical trials suggest the
important role of fenoﬁbrate for the treatment of PDR:
the FIELD (Fenoﬁbrate Intervention and Event Lowering in
Diabetes) study and ACCORD (Action to Control Cardio-
vascular Risk in Diabetes)-Eye study. These trials included
an aggregate of 11,388 patients with diabetes mellitus type
II, of which 5,701 were treated with fenoﬁbrate (±statin) for
up to 5 years. In the FIELD study, retinopathy progression
was deﬁned as laser treatment for PDR or macular edema
or an increase by ≥2 steps on the Early Treatment Diabetic
Retinopathy Study (ETDRS) scale. Disease progression in
the ACCORD-Eye study was deﬁned as an increase of ≥3
steps on the ETDRS scale or proliferative disease requir-
ing laser or vitrectomy treatment. In FIELD, fenoﬁbrate
(200mg/day) reduced the requirements for laser therapy
and was shown to arrest disease progression in patients
with preexisting diabetic retinopathy. In ACCORD-Eye,
fenoﬁbrate (160mg/day) taken with simvastatin yielded a
40% reduction in the odds of retinopathy progression when
compared with simvastatin alone over 4 years. Fenoﬁbrate
reduced ﬁrst laser treatment by 31% (P = 0.0002) and
progression of diabetic retinopathy with absolute reductions
of 5.0% over 5 years (P = 0.022, FIELD) and 3.7% over 4
years (P = 0.006, ACCORD-Eye) [74–77].
While the beneﬁts of fenoﬁbrates and statins have been
discussed as they apply to PDR, the beneﬁts of statins
on those with cardiovascular disease have been previously
established.Intherandomizedanddouble-blindedJUPITER
trial, 17,603 men and women without diabetes or established
cardiovascular disease were randomly assigned to rosuvas-
tatin 20mg or placebo and followed for up to 5 years as a
primary endpoint. The trial demonstrated that rosuvastatin
signiﬁcantly reduced the incidence of major cardiovascular
evidenceinotherwisehealthyindividualswithelevatedhigh-
sensitivity C-reactive proteins [78]. Although the results
suggested that rosuvastatin could also result in a small but
signiﬁcant risk of diabetes (as of February 2012, the USA
Food and Drug Administration added a new warning to
statin medications reﬂecting this risk), a subsequent study
analyzing the data from the JUPITER trial determined that
the risk of developing diabetes from statin therapy was
limited to those subjects with baseline high risk of devel-
oping diabetes, including those with evidence of impaired
fastingglucose,metabolicsyndrome,severeobesity,orraised
HbA1c. The authors emphasize that the cardiovascular and
mortalitybeneﬁtsofstatintherapyexceedtheriskofdiabetes
in the trial population as a whole as well as in participants
at increased risk of developing diabetes. Indeed, even among
those with high risk of diabetes, rosuvastatin was estimated
to prevent 134 heart attacks, strokes, or deaths, with an
additional 54 cases of diagnosed diabetes. In the low-risk
group, 86 heart attacks, strokes, or deaths were prevented,
with no new cases of diabetes [79].
The role of better blood pressure control on the pro-
gression of PDR is less clear. Though the ACCORD-Eye
and ADVANCE studies did not demonstrate any signiﬁcant
beneﬁtsofintensivebloodpressurecontrolonprogressionofMediators of Inﬂammation 7
diabetic retinopathy, the UK Prospective Diabetes Study did
[75, 80–82].
Coumarin has also recently been investigated as a
potential treatment for PDR. Mazzon et al. recognized the
essential role of retinal microvascular compromise in the
pathophysiology of PDR and investigated the eﬀects of
cloricromene on diabetes elicited by injection of streptozo-
t o c i ni nr a t s[ 83, 84]. An antiplatelet drug with vasodila-
tory and endothelial-preserving properties, cloricrome-
ne (ethyl 2-(8-chloro-3-(2-diethylaminoethyl)-4-methyl-2-
oxochromen-7-yl)-oxyacetate), is a semisynthetic coumarin
derivative that has been shown to mitigate chronic inﬂam-
mation and resultant tissue damage associated with arthritis
in rats [53]. The authors found that cloricromene signif-
icantly lowered retinal TNF-α, ICAM-1, VEGF, and nitric
oxidesynthase(eNOS)levelsandsuppresseddiabetes-related
BRB breakdown by 45%.
Many inhibitors have been developed to arrest the
progression of glycation and advanced glycation end prod-
ucts (AGE). It has been shown that prolonged oxidative
stresses in the context of diabetes result in the production
and accumulation of AGEs, receptor-independent agents
promoting vascular damage, ﬁbrosis, and inﬂammation.
Aminoguanidine, pyridoxamine, OPB-9195, LR-90, and
alagebrium chloride are all agents developed to address
AGE related damages [85, 86]. These have all demonstrated
variable levels of therapeutic eﬃcacy in diabetic complica-
tions. Most recently, Li et al. described the use of RAGE
inhibitors on early diabetic retinopathy and tactile allodynia
[87]. RAGE is the receptor for AGE, one of the pathway
mechanisms of microvascular damage due to hyperglycemia
in DR. The authors reported that RAGE fusion protein
inhibited capillary degeneration, albumin accumulation in
the neural retina, retinal protein nitration, tactile allodynia,
diabetes-related retinal leukostasis, and ICAM-1 expression,
although the eﬀects of the latter two were not statistically
signiﬁcant at low doses.
This paper serves as a review of the pathophysiology
leading to PDR and highlights the major interventional
opportunities for the treatment of this disorder. A literature
search for clinical markers associated with PDR is replete
with inﬂammatory factors and numerous mediators cur-
rently being investigated for their roles in PDR. As unique
markers associated with the pathophysiology of PDR are
discovered,furtherstudieswillbeneededtoevaluateeﬃcient
and eﬀective interventions targeted at deleterious mediators
and pathways in order to obviate microvascular disease from
progressing to fulminant PDR.
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